Histologically or cytologically confirmed HR+/HER2- recurrent or metastatic breast cancer.
Presence of a pathogenic PIK3CA mutation confirmed by tissue or plasma-based NGS/PCR testing.
Availability of traceable electronic medical records, imaging, laboratory, and follow-up data at baseline.
Initiated treatment with "Inavolisib + Endocrine Therapy" with or without a CDK4/6 inhibitor in real-world clinical practice, with complete and traceable regimen information.
Provision of informed consent for this non-interventional study (if required by the center's ethics committee).
You may not be if
Concurrent participation in any interventional clinical trial at enrollment.
Presence of another active malignancy requiring concurrent systemic therapy, or missing core data preventing outcome assessment.
Any condition (psychiatric, social, geographical) that would preclude adequate follow-up, as judged by the investigator.
Clareo Health | A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
